Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study

Several studies have reported the benefits and safety of heterologous vaccination among different approved vaccines; however, there are no specific reports on the effects of vaccination with the Ad5-nCoV and other vaccines of the same or different technologies. In the present study, we evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Valle, José Francisco, Sánchez-Zuno, Gabriela Athziri, Matuz-Flores, Mónica Guadalupe, Hernández-Ramírez, Cristian Oswaldo, Díaz-Pérez, Saúl Alberto, Baños-Hernández, Christian Johana, Turrubiates-Hernández, Francisco Javier, Vega-Magaña, Alejandra Natali, Hernández-Bello, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954152/
https://www.ncbi.nlm.nih.gov/pubmed/35335032
http://dx.doi.org/10.3390/vaccines10030400
Descripción
Sumario:Several studies have reported the benefits and safety of heterologous vaccination among different approved vaccines; however, there are no specific reports on the effects of vaccination with the Ad5-nCoV and other vaccines of the same or different technologies. In the present study, we evaluated the neutralizing antibodies percentage against SARS-CoV-2 in Mexican patients immunized with the Ad5-nCoV vaccine six months after its application. Moreover, the effect of the heterologous vaccination with the Ad5-nCoV vaccine and a booster dose of ChAdOx1-S-Nov-19, Ad26.COV2.S, BNT162b2, or mRNA-127 were determined. Our results suggest that a heterologous regimen of one dose with Ad5-nCoV vaccine followed by a booster dose of a different vaccine is safe and induces a stronger humoral immune response.

Ejemplares similares